Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.43 |
| ▸ | BRAF | P15056 | 11/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26074348 | 0.93 | BRAF (0.40) | RAF1BRAFANO1 | |
| SCHEMBL26075548 | 0.91 | BRAF (0.44) | RAF1BRAFANO1 | |
| SCHEMBL26074296 | 0.87 | CSF1R (0.46) | ANO1 | |
| SCHEMBL26075759 | 0.87 | BRAF (0.47) | RAF1BRAFANO1 | |
| SCHEMBL26075805 | 0.80 | BRAF (0.51) | RAF1BRAFANO1 | |
| SCHEMBL26075528 | 0.80 | DDR1 (0.45) | RAF1BRAF | |
| SCHEMBL26074472 | 0.80 | DDR1 (0.45) | RAF1BRAFANO1 | |
| SCHEMBL26075763 | 0.79 | GAA (0.51) | RAF1BRAF | |
| SCHEMBL26075774 | 0.79 | PYGL (0.43) | RAF1BRAFANO1 | |
| SCHEMBL26074299 | 0.77 | FLT3 (0.45) | RAF1BRAFANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | RAF1 115/4885BRAF 21/4885ANO1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.